On the other hand, osimertinib has shown significant brain penetration [3] and has demonstrated inhibitory activity against GBM in preclinical and clinical trials [4–6], thus offering great potential for the treatment of EGFR-driven GBM. Here, EGFR is linked to glioblastoma.